Kidney transplantation remains the treatment of choice for end-stage renal disease; however, long-term graft survival continues to be limited by alloimmune ...
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process ...
Greenwich LifeSciences reports preliminary HLA data from Phase III trial FLAMINGO-01 evaluating GLSI-100 for preventing breast cancer recurrences. Greenwich LifeSciences, Inc. provided an update on ...
STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, ...
A subset of neutrophils as a predictive biomarker for immunotherapy response in patients with non–small-cell lung cancer and melanoma. This is an ASCO Meeting Abstract from the 2023 ASCO Annual ...
Caribou Biosciences, Inc. experienced a 45% share price decline after presenting puzzling results for their product candidate CB-010 in a Phase 1 clinical trial. CB-010 showed limited efficacy in ...
A medical camp in Visakhapatnam provided free HLA typing and consultations for over 55 families affected by Thalassemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results